www.mazadapharmaguide.com Open in urlscan Pro
68.171.213.17  Public Scan

Form analysis
4 forms found in the DOM

POST View

<form method="POST" action="View">
  <div class="form-check-inline">
    <label class="form-check-label" for="radio1">
      <input name="optSearch" onclick="setType('P')" type="radio" class="form-check-input" id="radio1" value="Products" checked="">By Products </label>
  </div>
  <div class="form-check-inline">
    <label class="form-check-label" for="radio2">
      <input name="optSearch" onclick="setType('C')" type="radio" class="form-check-input" id="radio2" value="Companies">By Company </label>
  </div>
  <!--<div class="input-group-prepend">
								<span class="input-group-text">$</span>
							</div>-->
  <input name="txtSearch" type="text" class="form-control" id="txtSearchP" placeholder="Enter Products" style="width: 100%;margin-bottom: 10px;">
  <div class="input-group-append">
    <!-- <div data-toggle="modal" data-target="#myModal" id="btnGo" onclick="getCompProducts()" class=" form-control btn btn-primary"> Go</div> -->
    <input name="submit" value="Go" type="submit" class=" form-control btn btn-primary">
  </div>
</form>

POST ../Advertisers/index.php

<form method="POST" action="../Advertisers/index.php">
  <input type="text" class="form-control" style="width: 100%;margin-bottom: 10px;" id="OwnerInputEmail" name="OwnerInputEmail" placeholder="username">
  <input type="password" class="form-control" style="width: 100%;margin-bottom: 10px;" id="OwnerInputPassword" name="OwnerInputPassword" placeholder="password">
  <button class="form-control btn btn-warning" name="LoginBtn" type="submit">Login</button><br>
  <!--<button class="form-control btn btn-info" name="RegAdvtBtn" type="submit">New Advertiser</button>-->
</form>

POST DigitalEditions

<form id="DigitalE" action="DigitalEditions" method="POST">
  <input id="txtEdition525" name="txtEdition" type="hidden" value="The Mazada Pharma Guide">
</form>

POST DigitalEditions

<form id="DigitalE" action="DigitalEditions" method="POST">
  <input id="txtEdition" name="txtEdition" type="hidden" value="The Mazada Pharma Guide">
</form>

Text Content

X
X
Mazda Publications invites articles on Latest Products, Technology, Policy
Trends without being too Company/ Brand or Product specific.

Kindly email Your Contributions to:
Mr Anurag More
Sub Editor
Mazda Publications
Email: mazdapharmaguide@gmail.com
Www.chemicalsourcingguide.com


Printing of the Article will be at Sole Discretion of the Publisher and Reason
for acceptance or rejection of same is not answerable.
Mazada Pharma Guide

 * Home
   
 * About Us
   Company Profile Mission and Values Business Achievements
 * Pricing
   Print Tariff Print Packages Web Tariff Web Packages
 * Our Product
   
   MAGAZINES
   
   The Mazada Pharma Guide Chemical Sourcing Guide
   
   --------------------------------------------------------------------------------
   
   DIRECTORIES
   
   All India Formulators Directory All India API, Bulk Drugs Directory
   
   --------------------------------------------------------------------------------
   
   SUPPLEMENTS
   
   CPHI India Special Supplement - 2020
 * Contact
 * Subscription
 * Advertise with us
 * News

Find Suppliers
By Products
By Company

P
Advertisers'
Lead Manager
Login

Digital Editions
The Mazada Pharma Guide


PREMIUM ADVERTISERS

Profile
Visit Website Contact

Profile
Visit Website Contact

Profile
Visit Website Contact


ADVERTISERS

11







PPP



PR NEWSWIRE






News provided by PR Newswire
 * MATRIX PROVIDERS LAUNCHES MILITARY HEALTHCARE STAFFING EFFORTS FOR $43
   BILLION GOVERNMENT CONTRACT
   DENVER, 25 minutes ago
   Pioneers of MSP Model for Military Healthcare Staffing Continue to Ensure
   Medically Ready Force DENVER, May 22, 2024 /PRNewswire/ -- Matrix Providers,
   a prominent medical staffing provider for the…
 * For the Second Year in a Row, Veeva MedTech Named Best Overall Medtech
   Software
   PLEASANTON, Calif., 27 minutes ago
   Annual MedTech Breakthrough Awards program recognizes leading companies in
   medical devices and diagnostics PLEASANTON, Calif., May 22, 2024 /PRNewswire/
   -- Veeva Systems (NYSE: VEEV) today announced…
 * Medsien Named Veradigm Connect's App of the Month, Expands Relationship to
   Offer Unparalleled Remote Care Management Solutions
   SAN FRANCISCO, 30 minutes ago
   With its integration to Veradigm PM and EHR, Medsien continues to set new
   standards in remote care management SAN FRANCISCO, May 22, 2024 /PRNewswire/
   -- Medsien, a leading provider of remote care…
 * Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical
   Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
   VICTORIA, BC, 30 minutes ago
   VICTORIA, BC, May 22, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc.
   ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage
   biotechnology company leveraging its proprietary…
 * I-Mab to Participate at the Jefferies Global Healthcare Conference
   ROCKVILLE, Md., 30 minutes ago
   ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a
   U.S.-based global biotech company, exclusively focused on the development and
   potential commercialization of highly…
 * Chad Walter Joins DiningRD as Chief Financial Officer
   ST. LOUIS, 30 minutes ago
   ST. LOUIS, May 22, 2024 /PRNewswire/ -- DiningRD, the country's leading
   provider of nutrition consulting and foodservice software to senior living
   communities, announced today that Chad Walter has…
 * In Our UNITED Era: Walk ALS Chicago on June 1st
   WHEATON, Ill., 30 minutes ago
   WHEATON, Ill., May 22, 2024 /PRNewswire/ -- ALS United Greater Chicago is
   delighted to welcome you to the much-anticipated 2024 Walk ALS Chicago,
   taking place at the beautiful Cantigny Park in…
 * BioLineRx to Report First Quarter 2024 Results on May 28, 2024
   TEL AVIV, Israel, 30 minutes ago
   Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, May 22,
   2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial
   stage biopharmaceutical company pursuing…
 * BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM
   PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY
   MINNEAPOLIS, 30 minutes ago
   MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
   TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on
   the discovery and development of innovative…
 * Avaneer Health Announces the Launch of its Coverage Direct Solution
   OAK BROOK, Ill., 30 minutes ago
   Initial product launch reveals significant financial benefits for payers and
   providers OAK BROOK, Ill., May 22, 2024 /PRNewswire/ -- Avaneer Health, a
   decentralized digital network and platform for…
 * Global General Surgery Devices Market Size to Worth USD 30.33 Bn By 2031
   BURLINGAME, Calif., an hour ago
   BURLINGAME, Calif., May 22, 2024 /PRNewswire/ -- The global general surgery
   devices market size is calculated at USD 16.46 billion in 2023 and is
   expected to be worth around USD 30.33 billion by…
 * Amba Announces New President for North America
   NAPLES, Fla., an hour ago
   Amba Health and Care Expands Leadership Team to Drive Growth and Innovation
   in Senior Living Technology Sector NAPLES, Fla., May 22, 2024 /PRNewswire/ --
   Amba Health and Care, a leader in advanced…
 * Infinant Health Appoints New Team Members to assist with Drug Development
   DAVIS, Calif., an hour ago
   DAVIS, Calif., May 22, 2024 /PRNewswire/ -- Infinant Health, a privately-held
   company focused on changing the trajectory of human health by supporting the
   development and restoration of the immune…

1 2 3  >   >> 



NEWS

Flight Passengers from Thailand and Singapore to be universally screened in
addition to those from China and Hong Kong
Union Minister of Health & Family Welfare Dr. Harsh Vardhan chaired a review
meeting on preparedness for management of Novel Coronavirus with senior officers
of the Ministry, here today.
Cabinet Secretary also held a high-level review meeting on the preparedness for
Novel Coronavirus with Secretaries of Health, Civil Aviation, Textiles,
Pharmaceutical, DHR, and Dte. General of Foreign Trade (DGFT). Cabinet Secretary
has held five review meetings so far.
As of today, 52,332 passengers from 326 flights have been screened. A total of
97 symptomatic travelers picked up by the IDSP have been referred to the
isolation facilities. 98 samples have been tested of which 97 have been found to
be negative. The earlier positive case found in Kerala is being monitored and is
stable.
In addition, Secretary (HFW) had a video conference to review the process of
screening passengers from different countries. Apart from passengers coming from
China and Hong Kong, passengers coming on flights from Singapore and Thailand
shall also be universally screened at the airports, henceforth. Shri Pradeep
Singh Kharola, Secretary (Civil Aviation), Health Secretaries from all States
for the 21 airports, Airport Public Health Officers from these airports, along
with representatives from the Bureau of Immigration, Customs Department were
present.
The 324 incoming Indian citizens from Wuhan, China have reached today. Of these,
104 are housed at ITBP Chawla Camp and 220 are in Manesar. They are being
effectively monitored.
New Beginning for Indian Pharmaceuticals and Standards
The Indian Pharmacopoeia (IP) has been recognised formally by the National
Department of Regulation of Medicines and Health Products of the Ministry of
Public Health of Islamic Republic of Afghanistan. It will also be used based on
the requirement as reputable pharmacopoeia in the laboratory of medicines and
health products quality. With this, a new beginning has been made and
Afghanistan has become the first country to recognize IP pursuant to the efforts
of Department of Commerce and Ministry of Health and Family Welfare.
IP is an officially recognized book of standards as per the Drugs and Cosmetics
Act, 1940 and Rules 1945 thereunder. The IP specifies the standards of drugs
manufactured and marketed in India in terms of their identity, purity and
strength.
The quality, efficacy and safety of the medicines are important from healthcare
perspective. In order to ensure the quality of medicinal products, the legal and
scientific standards are provided by Indian Pharmacopoeia Commission (IPC) in
the form of Indian Pharmacopoeia (IP). As per, the Second Schedule of the Drugs
and Cosmetics Act, IP is designated as the official book of standards for drugs
imported and/or manufactured for sale, stock or exhibition for sale or
distribution in India.
The IP Commission’s mission is to promote public and animal health in India by
bringing out authoritative and officially accepted standards for quality of
drugs including active pharmaceutical ingredients, excipients and dosage forms,
used by health professionals, patients and consumers. This is achieved by
developing the standards for medicines and supporting their implementation. In
addition, IPC also develops IP Reference Substances (IPRS) that act as
fingerprint for identification of an article under test and its purity as
prescribed in the IP monographs. Standards prescribed in the IP are
authoritative in nature and are enforced by the regulatory authorities for
quality control of medicines in India.
Setting up of National Investment & Manufacturing Zones
Government notified the National Manufacturing Policy(NMP) in 2011. The Policy
is based on the principle of industrial growth in partnership with the States.
National Investment & Manufacturing Zones (NIMZs) are one of the important
instruments of the policy. Government has already granted final approval to the
NIMZ in Sangareddy district, Telangana. Further, the proposal for granting final
approval of establishment of Hyderabad Pharma City NIMZ in Rangareddy district,
Telangana has been considered and recommended by the High Level Committee (HLC).
A letter of Chief Minister of Telangana was received in which CM has requested
to release an amount of Rs. 500 Crores for development of external and internal
infrastructure under Phase-1 of Zaheerabad NIMZ in Sangareddy district of
Telangana. In this regard, Department for Promotion of Industry and Internal
Trade(DPIIT) had already conveyed to the State Government of Telangana that
DPIIT’s financial commitment is limited to extending assistance of Rs. 3 crores
for funding the cost of master planning. For development of infrastructure in
the NIMZ, the role of DPIIT is limited to coordination and no finances from
DPIIT are committed for this purpose. The project proposals need to be prepared
by the State Government and processed for approval as per norms and procedures
applicable to Central Sector/ Centrally Sponsored/State Sector schemes/projects.
DPIIT will forward such requisitions to the concerned Ministries and coordinate
between State Government and line Ministries.
DPIIT has already released Rs. 3 Crores to the SPV of NIMZ for funding the cost
of master planning of NIMZ in Sangareddy district of Telangana. The Department
had also forwarded the proposals, submitted by TSIIC, of External infrastructure
linkages, i.e. Road linkages and Rail linkages, for phase-1 of the said NIMZ to
the Ministry of Road Transport and Highways and Ministry of Railways
respectively. The comments of Ministry of Railways have already been conveyed to
Government of Telangana. Further, no proposal for internal infrastructure in the
NIMZ has been received from the State Government.
The progress of NIMZ in Sangareddy district of Telangana was further reviewed on
14th November, 2019, in the 6th meeting of High Level Committee.
This information was given by the Minister of Commerce and Industry, Piyush
Goyal, in a written reply in the Lok Sabha today.
Cabinet approves extension/renewal of the extant Pharmaceuticals Purchase Policy
(PPP) with the same terms and conditions.
The Union Cabinet chaired by Prime Minister Shri Narendra Modi today approved
extension/renewal of Pharmaceuticals Purchase Policy (PPP) for pharmaceutical
Central Public Sector Undertakings (CPSUs) till their closure/strategic
disinvestment.
Major Impact
Extension/renewal of the policy would help the pharma CPSUs in optimum
utlilization of their existing facilities, enable them to generate revenues to
pay salaries to their employees, help them in keeping the costly, sophisticated
machinery in running condition resulting in higher return at the time of
disposal in case of CPSUs under closure and better valuation in case of CPSUs
under disinvestment.
Background
Pharmaceuticals Purchase Policy (PPP) was approved by the Cabinet on 30.10.2013
for a period of five years in respect of 103 medicines manufactured by pharma
CPSUs and their subsidiaries. The policy is applicable to purchases by Central/
State Government departments and their Public Sector Undertakings etc. The
pricing of the products is done by National Pharmaceutical Pricing Authority
(NPPA). The procuring entity can purchase from Pharma CPSUs and their
subsidiaries subject to their meeting Good Manufacturing Practices (GMP) norms
as per Schedule ‘M’ of the Drugs & Cosmetic Rules. The term of the policy
expired on 09.12.2018.
Meanwhile, Cabinet decided on 28.12.2016 to close Indian Drugs and
Pharmaceutical Limited (IDPL) & Rajasthan Drugs and Pharmaceuticals Limited
(RDPL) and strategically sell Hindustan Antibiotics Limited (HAL) & Bengal
Chemicals and Pharmaceutical Limited (BCPL), after meeting their liabilities
from proceeds of sale of their surplus land to government agencies.
Subsequently, Cabinet has modified its decision on 17.07.2019 permitting to sell
surplus land as per revised Department of Public Enterprises guidelines dated
14.06.2018. Separately, Cabinet Committee on Economic Affairs (CCEA) decided on
01.11.2017 for disinvestment of 100% GOI equity in the fifth pharma CPSU, namely
Karnataka Antibiotics & Pharmaceuticals Limited (KAPL).
It has been proposed to extend the policy till final closure/sale of pharma
CPSUs.
Digital Editions 2024
The Mazada Pharma Guide

Media Partner





--------------------------------------------------------------------------------

Pharma India Expo

--------------------------------------------------------------------------------



--------------------------------------------------------------------------------

Asia Labex

--------------------------------------------------------------------------------

Ankeleshwar Industrial Expo

--------------------------------------------------------------------------------

India Lab Expo & Analytica Anacon India

--------------------------------------------------------------------------------

Asia Labex

--------------------------------------------------------------------------------

IPHEX

--------------------------------------------------------------------------------

Pharmac South

--------------------------------------------------------------------------------

Pharma Pro&Pack Expo

--------------------------------------------------------------------------------

India Lab Expo & Analytica Anacon India

--------------------------------------------------------------------------------

CPHI India

--------------------------------------------------------------------------------

Industrial Expo

--------------------------------------------------------------------------------

Pharma Live Expo

--------------------------------------------------------------------------------

HPCI

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------


ADDRESS

1 A , Sharma Compound , Old Nagardas Road
Opp Abhudaya Bank , Andheri East, Mumbai
Maharashtra 400069


EMAIL

mazdapharmaguide@gmail.com




CONTACT

8652813388

Designed by Humans Information Technology Solutions
Copyright: Mazda Publications
Digital Editions ×

Leads ×